ABOUT US
Adcock Ingram at a glance
VIEW FULL AT A GLANCE
FINANCIAL CAPITAL*
Turnover
R6 540m
(2017: R5 936m)
INTELLECTUAL CAPITAL
The South African private pharmaceutical market, as measured by IQVIA MAT June 2018, is worth R42.9 billion, with 7.1% value and 4.9% volume growth (including new products).
NATURAL CAPITAL
Energy usage (kWh)
50 379m
(2017: 49 456m)
MANUFACTURED CAPITAL
| BANGALORE (JV facility) |
Capacity – Tablets and capsules: 3,5 BILLION UNITS |
|
| Accreditations: | Nigeria (NAFDAC), | |
| UK (MHRA), | Ghana (FDB), | |
| Australia (TGA), | Namibia (NMRC), | |
| South Africa (SAHPRA), | Uganda (UNDA), | |
| France (ANSM), | Zimbabwe (MCAZ), | |
| Tanzania (TFDA), | Malawi (PMPB), and | |
| Kenya (PPB), | Ethiopia (FMHACA) |
SOCIAL AND
RELATIONSHIP CAPITAL
B-BBEE SCORE
LEVEL 3
HUMAN CAPITAL
Employees
2 610
- OUR BUSINESS MODEL
- STRATEGIC PERFORMANCE
The progress made over the past year has put the business in a more sustainable position, within the tough economic climate and socio-political conditions within which the business is operating. The front-end focus remained on Customers, Products and Service, with strict attention to quality, efficiencies and costs at the back-end. The business continues to explore growth and expansion opportunities.
Adcock Ingram presented its priorities at the start of the financial year which incorporated the following three focus areas:
1 |
 |
PILLAR 1 |
2 |
 |
PILLAR 2 |
3 |
 |
PILLAR 3 |
|||||||
OUR PEFORMANCE
Leadership review from
our Chairman and CEO
VIEW CHAIRMAN AND CEO REVIEW
INTRODUCTION
With another successful financial year behind us, we are pleased to present the Company's 2018 Integrated Report to stakeholders. Despite a multitude of challenging factors, our financial results are testament to the fact that the business is progressing at a balanced pace. Our commitment and promise are very much evident through the efforts of all divisions, who are focused on living up to our values and ethos of 'Adding value to life'. Heart-warming initiatives include the launch of the"Shoes for Africa" project with Netcare as well as the introduction of the new Claria peritoneal dialysis machine by our Hospital business which both added value to the lives of the people we serve.
Through humble beginnings that date back to 1890, starting off as a community pharmacy in Krugersdorp, Adcock Ingram celebrated ten years of being a relisted company on the Johannesburg Stock Exchange (JSE) on 25 August 2018. Today the Company has a market capitalisation of over R10 billion.
VIEW CHAIRMAN AND CEO REVIEW- OVER THE COUNTER
- PRESCRIPTION
- HOSPITAL
- CONSUMER
OVER THE COUNTER (OTC)
VIEW OVER THE COUNTER (OTC)
WERNER VAN RENSBURG
Managing Director
NATALIE ZAROUDOUKAS
Financial Director
Turnover
R1 989m
(2017: R1 849m)
Top 10 brands
turnover
R1 131m
Trading profit
R400m
(2017: R342m)
Sales
MARKET SHARE
-
Volume market position(1) #1
-
Value market position(1) #1
-
Value market share(1) 21.6%
-
Volume market share(1) 34.8%
-
Script share(2) 36.00%
-
(1) IQVIA MAT Jun 2018 S1 and S2 (2) Impact Rx Jun 2018 constructed (categories in which we compete)
NUMBER OF EMPLOYEES
-
433 factory and laboratory
-
160 sales, marketing and administration
TOP BRANDS
-
Adco-Dol
-
Allergex
-
Corenza C
-
Citro Soda
-
Alcophyllex
-
Adco-Napamol
-
Betapyn
-
Solphyllex
-
Dilinct
-
Mypaid
MANUFACTURING
-
28 million effervescent tablets
-
400 tonnes Effervescent granules and powders
-
12 million ℓ
Oral liquids -
Accreditations
South Africa (SAHPRA), Ghana (FDB), Malawi (PMPB), Kenya (PPB), Zimbabwe (MCAZ), and Ethiopia (FMHACA). -
Location
Clayville
PRESCRIPTION
VIEW PRESCRIPTION
ADISHA SINGH
Financial Director
ASHLEY PEARCE
Managing Director
Turnover
R2 238m
(2017: R1 938m)
Top 10 brands
turnover
R803m
Trading profit
R239m
(2017: R208m)
Sales
MARKET SHARE (1)
-
Value market share 7.0%
-
Value market position #3
-
Volume market share 10.9%
-
Volume market position #2
-
ARV private market share 16.6%
-
(1) IQVIA MAT Jun 2018, including MNC partnerships
NUMBER OF EMPLOYEES
-
320 factory and laboratory
-
212 sales, marketing and administration
-
126 in Genop
TOP BRANDS
-
Trivenz
-
Genpayne
-
Adco-Zolpidem
-
Myprodol
-
Topzole
-
Synaleve
-
Estrofem
-
Urizone
-
Xylotox
MANUFACTURING
-
6 million ℓ
Oral liquids -
500 tonnes Creams/Ointments
-
2 billion
Tablets and capsules -
Accreditations
South Africa (SAHPRA), Ghana (FDB), Malawi (PMPB), Kenya (PPB), Zimbabwe (MCAZ), and Botswana (DRU). -
Location
Wadeville
HOSPITAL
VIEW HOSPITAL
COLIN SHEEN
Managing Director
MOHAMED MANGEL
Financial Director
Turnover
R1 348m
(2017: R1 257m)
Trading profit
R95m
(2017: R58m)
Sales
MANUFACTURING
Capacity per annum
-
33 million
large volume parenterals -
35 million
small volume parenterals -
4 million
pour bottles -
1 million
Blood collection bags -
Accreditations
South Africa (SAHPRA), and Kenya (PPB) -
Location
Aeroton
-
Only medical grade LVP plastic manufacturer on the continent
-
Extrude >1 900 metric tons of PVC sheeting and tubing per annum
NUMBER OF EMPLOYEES
-
115 sales, marketing and administration
-
648 factory
CONSUMER
VIEW CONSUMER
GAIL SOLOMON
Managing Director
LAUREN SHIMMIN
Financial Director
Turnover
R687m
(2017: R689m)
Top 10 brands
turnover
R629m
Trading profit
R112m
(2017: R110m)
Sales
MARKET SHARE1
-
Analgesics
30% -
Feminine hygiene
49% -
Energy
supplements
41% -
Gut Health
27% -
Suncare
2%
NUMBER OF EMPLOYEES
-
68 sales, marketing and administration
TOP BRANDS
-
Panado
-
Bioplus
-
ProbiFlora
-
Compral
-
Gyna Guard
-
Cepacol
-
Gummy Vites
-
Viral Guard
-
Island Tribe
-
Freshen
SALES BY CUSTOMER
CHANNEL
1 Source: ACNielsen June 2018 – defined market comprises the category, customers and channels for the segments in which we compete